Cytori Therapeutics Inc., of Austin, Texas, is changing its name to Plus Therapeutics Inc. to reflect its new focus on developing innovative drugs. It has reserved a new stock symbol, PSTV, and plans to submit notice of the company name change to Nasdaq.

Neuralstem Inc., of Germantown, Md., completed a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split becomes effective Wednesday. The split enables Neuralstem to regain compliance with the $1 minimum bid price condition of Nasdaq.

Flex Pharma Inc., of Boston, said its stockholders approved all proposals relating to its planned merger with Houston-based Salarius Pharmaceuticals LLC at its special meeting. The merger is expected to be completed within the next two weeks.

Sonoma Pharmaceuticals Inc., of Petaluma, Calif., said it is now compliant with the minimum bid price requirement for continued listing on Nasdaq and is no longer subject to delisting at this time. To achieve compliance, the company implemented a 1-for-9 reverse stock split last month.

Schrodinger Inc., of New York, said it received a preclinical milestone payment from Sanofi SA, of Paris, in a drug discovery program advancing as part of a multiyear, multitarget collaboration.

Volitionrx Ltd., of Austin, Texas, was awarded a $1.4 million grant from the Walloon Region in Belgium to support a collaboration with Giga at the University of Liege, Belgium. The project will study the use of telomere maintenance as a cancer diagnostic using Volitionrx's Nucleosomics platform.

Cytomx Therapeutics Inc., of South San Francisco, will receive a $10 million payment from Abbvie Inc., of North Chicago, for the selection of a second target under their 2016 collaboration to discover and develop Probody drug conjugates.

Batavia Biosciences BV, of Leiden, the Netherlands, received a follow-up grant of $2.2 million from the global nonprofit Path, to develop and manufacture novel oral poliovirus vaccines. 

Novelion Therapeutics Inc., of Vancouver, British Columbia, received written notice from Nasdaq that it is not in compliance with the continued listing requirement to maintain minimum market value of publicly held shares of $15 million.